Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;127(8):1383-1384.
doi: 10.1038/s41416-022-01930-3. Epub 2022 Sep 5.

Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate

Yimin Wang #  1 , Hedong Han #  2 , Fang Zhang  2 , Tangfeng Lv  2 , Ping Zhan  2 , Mingxiang Ye  2 , Yong Song  3   4 , Hongbing Liu  5
Affiliations
Comment

Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate

Yimin Wang et al. Br J Cancer. 2022 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

References

    1. Alessandro R. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br J Cancer (letter to the editor submitted). - PMC - PubMed
    1. Wang Y, Han H, Zhang F, Lv T, Song Y, Liu H, et al. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. Br J Cancer. 2022. 10.1038/s41416-022-01832-4. - PMC - PubMed
    1. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46. doi: 10.1016/S0140-6736(16)00587-0. - DOI - PubMed
    1. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130–7. doi: 10.7326/0003-4819-159-2-201307160-00008. - DOI - PubMed
    1. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103–11. doi: 10.1007/s11739-016-1583-7. - DOI - PMC - PubMed

MeSH terms

Substances